![]() ![]() ![]() She was treated with hydrochlorothiazide for her hypertension and citalopram for depression. There was no family history of sudden cardiac death (SCD). She denied any history of palpitations, syncope, or pre-syncope. Her vital signs included heart rate (HR) of 80 bpm, blood pressure of 135/76 mm Hg, and respirations of 12 per minute. In the cardiology clinic, she appeared comfortable and was without complaints. ![]() Given that nilotinib has a black box warning issued by the Food and Drug Administration for QT interval prolongation, she was referred to the cardiology clinic for further evaluation. Prior to initiating nilotinib, a baseline ECG was obtained that demonstrated a QTc of 505 ms using Bazett's formula. As such, her oncology team was interested in starting nilotinib, a different tyrosine kinase inhibitor as second-line therapy to control her cancer. However, she demonstrated progression of disease while on this agent. She was initially treated with imatinib, a tyrosine kinase inhibitor. She was diagnosed with chronic myelogenous leukemia approximately 1 year prior to presentation. A 55-year-old woman with a past medical history of hypertension, mild depression, and chronic myelogenous leukemia is referred to cardiology clinic for evaluation of an abnormal electrocardiogram (ECG). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |